In a phase 2 trial, nivolumab or combination nivolumab/ipilimumab (CTLA-4 inhibitor) was administered to 27 patients with resectable HCC as neoadjuvant therapy and for 2 years post-resection as adjuvant immunotherapy. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.